+1,609.3%
VRT vs MRNA
+786.4%
+822.9%
-71.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -10.1% | -2.2% | -8.0% | -10.0% |
| 7D | -17.7% | -12.7% | -5.0% | -17.2% |
| 30D | -21.6% | -20.7% | -1.0% | -20.9% |
| 3M | -37.2% | +46.3% | -83.4% | -38.3% |
| 6M | -47.3% | +305.2% | -352.6% | -53.5% |
| YTD | +2.7% | +561.2% | -558.6% | -14.0% |
| 1Y | +4.3% | +772.1% | -767.8% | -15.0% |
| 3Y | +274.6% | +147.0% | +127.6% | +230.1% |
| 5Y | +519.3% | -26.1% | +545.3% | +466.0% |
| All | +1,609.3% | +786.4% | +822.9% | +1,718.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling